Is pollution from the steel industry behind cancer rates in Gary, Indiana?
Doctors, environmental groups and residents are trying to figure out if there is a causal connection between pollutants from the steel industry and rates of cancer in Gary, Indiana.
Pollutants you can see, and tiny particulates you can't, come from different types of industry in the Gary region. But according to Environmental Protection Agency records, steel production plants release the most toxins of all the industries in the region.
Beryl Fitzpatrick is one of the residents affected. You can hear the cancer as she speaks.
"I was having trouble swallowing," she recalled.
Fitzpatrick was diagnosed with Stage 3 tongue cancer. She didn't know if she would ever speak again after doctors removed part of her tongue while removing a cancerous tumor, but she fought to keep her voice.
"I had to learn phonics. I had to learn, I had to learn words and sounds," she said. "It was humbling."
And she knows the very air in her own backyard could be playing a role in her disease.
"It's almost certain that her place of residence, with the high pollution and other industrial output contributed to her cancer," said Dr. Kerstin Stenson, lead of the head and neck cancer program at Rush University Medical Center who's been treating Fitzpatrick.
The City of Gary was built by the steel industry, but when families like Fitzpatrick's moved to the region in droves from the South during the Great Migration for jobs and opportunities, they didn't know as much as we do now about the health risks linked to industrial production.
"A lot of the teachers would talk about students that had asthma," Fitzpatrick said.
Seven major coal-powered steel production plants operate in the United States. Three plants are clustered in the Gary region: Burns Harbor, Gary Works and Indiana Harbor.
CBS News Chicago Investigators dug into state and federal data from the Environmental Protection Agency to see how these facilities impact the community.
Our investigation found that in 2023, the latest data available, the three mills emitted 25 million pounds of toxins, more industrial pollution than the combined toxic release of the four similar mills in other states.
"We do not need to sacrifice health and communities to make steel," said Hilary Lewis, a director of Industrial Labs.
Industrial Labs, a nonprofit environmental organization, released a report in October 2024 detailing its findings on the steel industry's impact on the community.
"The people in Northwest Indiana are bearing the brunt of the coal-based steel industry today," she said.
The study found people living near one steel production facility have a 12% to 26% higher risk of getting cancer. People in Gary live near three.
And cancer isn't the only health risk associated with this kind of industrial exposure.
Industrial Labs' study found people living in Gary are in the top 10% of the nation at risk for developing asthma. Even Gary Mayor Eddie Melton grew up with asthma, and the irony of the steel industry that built the city now being the thing making people sick is not lost on him.
"I mean, that's a stark reality that a lot of folks have to deal with," Melton said.
The mayor wants this dealt with, in part, by toughening toxic emissions standards. But that may not happen; in March, the federal EPA announced it's considering lowering some standards polluters must meet.
"What we're seeing from a federal and state government concerns me, in terms of rolling back the regulations on industries such as the steel industry, and other industries," Mayor Melton said.
Gary already fails to meet federal air quality standards. Lake County, Indiana has more toxic releases than 99% of all other counties across the country, and the state ranks second in the nation for the most industrial pollution released per square mile.
So what is the EPA doing for the people of Gary?
"They're responsible for protecting clean air," Lewis said. "And right now, they're not doing that."
CBS News Chicago Investigatiors dug into EPA records dating back to 1977 and found that since then the EPA took 152 formal actions against the steel production facilities. Nearly half of those actions were for violating the Clean Air Act. For those air pollution violations, regulators issued more than $23 million in penalties paid by the parent companies.
"If you're a multi-billion-dollar corporation, fees and fines probably are just a drop in the bucket for you," Melton said.
Both the state and federal EPA declined interviews but sent statements saying they act when facilities are out of compliance, and those actions have reduced air emissions.
Fitzpatrick lives about 43 blocks from the largest steel mill in the nation, and we found they released more pollutants than any other steel or iron mill tracked by the EPA across the country.
More than half the industrial pollution in Lake County comes from Gary Works, which is owned by U.S Steel.
U.S. Steel declined an interview, but responded to questions by email, saying the EPA's data includes byproducts "legally emitted," and said they have systems in place to comply with environmental regulations.
In regards to the Industrial Labs report, U.S. Steel said it was "designed to create media attention rather than reach any scientific conclusions."
Fitzpatrick has lived in Gary for 60 of her 71 years, never fully knowing what she was exposed to.
"I didn't think I was living a lifestyle that was polluting my body," she said.
She wasn't. Dr. Stenson said Fitzpatrick doesn't have the typical risk factors for her cancer. And she's not alone.
"There are many patients that have come from that industrial area that would present with head and neck cancer without risk factors," Stenson said.
Gary has been notorious for its pollution for decades.
Dr. Mihir Bhayani, also at Rush University Medical Center, is getting closer to directly linking air pollution and some cancers. The new research he is working on could force change.
"What we are working on currently is, again, a direct causal link between air pollution and head and neck cancer," he said.
He believes steel mills are making people sick in Gary, and he wants to see emissions standards toughened.
"So that individuals who are living in those areas, they're exposed to the same clean air that individuals who are living in more affluent areas are," he said.
"The types of communities that this industry is impacting are disproportionately people of color and low-income communities," said Lewis.
More than 76% of Gary's population is Black, and the average income is less than $23,000 a year.
About four hours away from Gary by car is the steel plant in Middletown, Ohio. It's getting a major portion of a $500 million federal grant to change the steel-making process and cut hazardous pollution in that city, which has an average income of $30,000 a year and is 73% white.
Fitzpatrick believes more would be done to keep the air clean and her community healthy if Gary's demographics were different.
"I am worthy. No matter what you think about my Black skin, my dark skin, I'm worthy. I'm worthy for this community to be cleaned up and I am a person worthy of a good life," she said.
Gary and other communities found to be disproportionately impacted by pollution were getting extra help from the federal EPA's Environmental Justice office, but in April it was labeled a DEI program and shut down.
If nothing is done, Bhayani said, there will be long-term effects on people living in communities like Gary.
"They are going to have higher rates of cancer. They're going to have higher rates of cardiac disease. They're going to have high rates of lung disease," Bhayani said.
That's why Fitzgerald, who fought for her voice while still battling the disease that nearly took it, said she'll do whatever it takes to make change here so that it can be different for someone else.
"As long as I have breath and I can breathe and I have strength to get up, I'm going to join other people, like-minded people. We're going to fight. We're going to fight," she said.
Cleveland Cliffs, which owns two of the plants in Northwest Indiana, did not return messages from CBS News Chicago Investigators. U.S. Steel maintains its work is essential to the health of the American economy.
But Fitzgerald and others who live there worry about their own health, and they're asking lawmakers to step up and join their fight for cleaner air.
The CBS News Race & Culture Unit and CBS News Data team contributed to this report.
FULL STATEMENTS
U.S. Steel
On whether they have studied the impact of releases from Gary Works and the health effects, including cancer and asthma, in the community:
"In 2020, the EPA deemed that there was an ample margin of safety around iron and steel emissions to protect public health and prevent adverse environmental effects."
It is important to note that there are many industrial facilities in Northwest Indiana. Focusing solely on Gary Works as a source of pollution is both incorrect and irresponsible.
On the study released by Industrial Labs:
"It is clear that these conclusions were pre-determined by a group that describes itself as 'scaling campaigns and building a movement to clean up heavy industry', which is to say that this document is designed to create media attention rather than reach any scientific conclusions. There are certain interests campaigning to eliminate U.S.-based blast furnaces, which are essential to national security and the health of America's economy because they are the only facilities capable of making certain types and qualities of steels required for critical applications."
On residents believing toxic releases would not be allowed at the same level in more affluent communities with different demographics:
"Federal and state emissions laws and regulations apply equally to any municipality in the same jurisdiction. Gary, Indiana, is no exception. We care deeply about the communities where we live and work, as evidenced by the contributions by the Company and our employees. Since 2020, U. S. Steel Gary Works and its employees have donated over $1.3 million dollars to community organizations and efforts. In addition, our dedicated employees volunteer countless hours of their time to organizations and schools across the area. Our more than 3,400 Gary Works employees put safety and environmental compliance first. We are proud of their work and the Northwest Indiana community we call home."
"In addition to our spend on environmental compliance and community investment and engagement, we were the only U.S. Metals, Minerals and Mining company recognized as one of the World's Most Ethical Companies for 2025- the fourth consecutive year we received this designation. It is a testament to our commitment to ethical conduct and compliance."
"Gary Works was built in 1908, and the city was built around it. Any notion that we select certain areas to operate because of their demographics is wholly incorrect."
On state and federal EPA fines, violations and consent decrees:
"U. S. Steel spends more than $80 million annually on environmental controls in Indiana as part of its commitment to environmental excellence. The EPA's Toxic Release Inventory, from which this data is drawn, includes manufacturing byproducts that are legally emitted under the EPA's stringent regulations and those which are legally disposed of in permitted landfills. As the nation's largest integrated steelmaking facility, it is common sense that U. S. Steel's Gary Works will have more legally allowed releases than smaller iron or steel mills in the country."
Additional comment on emissions controls and other projects:
"U. S. Steel has robust systems and emissions control equipment at all levels of the steelmaking process to adhere to environmental regulations.
At Gary Works, our processes and environmental controls are monitored extensively by our teams. Third parties are also used for sampling water and for opacity observation to ensure compliance with regulations.
Our partnership with CarbonFree is one of the ways we're working to reduce emissions. This carbon capture and utilization project will help us reduce greenhouse gas emissions by converting emissions to calcium carbonate, which is used in a variety of products for consumers and industry. Gary Works also produces Pig Iron, an important feedstock for U. S. Steel's electric arc furnaces. The Company is on track to meet its goal of 20% greenhouse gas emissions reduction by 2030 goal and has a goal of net zero greenhouse gas emissions by 2050."
Indiana Department of Environmental Management
IDEM is not a health agency nor a legislative body. IDEM is also not involved in local zoning decisions that determine where businesses are located.
IDEM is responsible for implementing and enforcing existing federal and state environmental regulations. This includes issuing operating permits that ensure businesses comply with applicable environmental standards and conducting routine inspections to monitor compliance. When facilities are found to be out of compliance, IDEM can initiate enforcement actions or refer cases for further legal or administrative review.
The U.S. EPA does require states to submit a state implementation plan (SIP) for areas in nonattainment within its borders. You can find more information on the SIPs for Lake and Porter counties here: https://www.in.gov/idem/sips/
In 2013, IDEM conducted an assessment of air toxics in the industrialized area of Lake and Porter County. The complete Lakeshore Air Toxics Study is available here: https://www.in.gov/idem/toxic/studies/lakeshore-air-toxics-study. The study found air toxics concentrations and risk within the lakeshore area to be similar to comparable communities, and the most significant risk is attributable to mobile sources (motor vehicles). In the time since the study, technological advances and pollution prevention strategies have led to a further decline in industrial emissions.
We recognize that air quality is a deeply important issue for Northwest Indiana residents and remain committed to our responsibilities under the Clean Air Act and other applicable laws. For more specific responses to questions involving federal enforcement actions, health data, or proposed changes to emission standards, we encourage you to follow up directly with the U.S. EPA.
U.S. Environmental Protection Agency
EPA is fulfilling its mission to protect human health and the environment. The agency works with our state partners to ensure industrial facilities comply with all environmental laws and regulations.
EPA performs on-site and off-site inspections to ensure compliance. If noncompliance is found, EPA takes action. EPA has issued three recent Clean Air Act enforcement settlements, which have significantly reduced air emissions. In Burns Harbor, Cleveland Cliffs BOF steel making shop and Phoenix Global slag processing companies and in Gary, the U.S. Steel Gary Works' blast furnace have all decreased particulate matter and metal hazardous air pollutants to the atmosphere. Our state partner, the Indiana Department of Environmental Management, also conducts inspections and enforcement actions.
Previous compliance and enforcement work, including inspections and enforcement activity, can be found in EPA's ECHO system. You can search by location or by facility. Keep in mind that the integrated iron and steel mills that you reference may have contractors on site that have separate permits and emissions reporting.
The northern portions of Lake and Porter Counties are part of a larger Chicago area that was found to be out of compliance with the ground-level ozone (or "smog") standard. Ozone high in the atmosphere protects people from harmful ultraviolet rays but at ground-level it can trigger a variety of health problems, such as lung irritation.
To learn more about attainment areas, visit our website.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
14 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
14 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
Associated Press
14 minutes ago
- Associated Press
Banyan & Bamboo Launches AI-Powered '365 Beauty Blueprint' for Personalized Aesthetic Wellness in Austin
Austin's most soulful med spa is now one of its smartest. Banyan & Bamboo Day Spa + Med Spa unveils the '365 Beauty Blueprint' - a regenerative aesthetic protocol blending advanced facial mapping with deeply personalized, year-round wellness planning. Austin, TX, Texas, United States, June 21, 2025 -- Women-Led Spa Debuts Year-Round Aesthetic Strategy Backed by AI Banyan & Bamboo Day Spa + Med Spa, a boutique, women-led studio in the heart of Austin, today announces the launch of its signature 365 Beauty Blueprint, a highly personalized treatment plan guided by advanced AI skin mapping. This milestone reflects the spa's commitment to natural, data-backed results in regenerative aesthetics, setting a new standard for long-term self-care. In a field often driven by fleeting trends and one-size-fits-all treatments, Banyan & Bamboo introduces a new kind of beauty planning - one rooted in personalization, cellular science, and soulful care. Banyan & Bamboo's AI skin analysis and 365-day treatment plan is one of the most personalized options for injectables and facial care in Austin. 'We don't believe in one-size-fits-all beauty,' says Jennifer Rushing, Owner and Founder. 'We co-create yearlong blueprints that support skin, confidence, and health from the inside out.' Precision Meets Personalization: The 365 Beauty Blueprint At the heart of the new offering is AI-powered skin analysis - a diagnostic tool that maps hydration, pigmentation, texture, sun damage and aging markers. These insights allow the team to design evolving treatment plans that respond to each client's changing skin needs. The 365 Beauty Blueprint integrates: Every service within the protocol is selected to support internal wellness and natural-looking refinement. Regenerative Aesthetics in a Spa-Like Setting Blending clinical innovation with spa-caliber care, Banyan & Bamboo offers a slower, deeper, and more restorative alternative to volume-focused chains. Each visit includes in-depth consultation, customized protocols, and education - empowering clients to feel confident, cared for, and in control of their treatment journey. 'Our clients aren't here for a quick fix,' says Lindsey R., Spa Manager and Guest Experience Coordinator. 'They come to us because we spend time, educate them, and offer treatments that support long-term beauty and wellness.' Shifting the Industry Toward Longevity and Intention Since opening its doors, Banyan & Bamboo has cultivated one of the most loyal client communities in Central Texas. With the 365 Beauty Blueprint, the studio deepens its philosophy: beauty is not a single service, it's a long-term relationship. From hormone-safe skincare to regenerative injectables, each blueprint is crafted with intention and backed by science. The result is an customized aesthetic plan that's as restorative as it is effective - one that meets modern clients where they are and grows with them. 'Austin deserves more than cookie-cutter med spas,' adds Rushing. 'Our goal is to bring intention, expertise, and a little bit of Austin soul into every appointment.' Award-Winning Service In addition to the launch of the 365 Beauty Blueprint, Banyan & Bamboo is also celebrating a recent recognition as the Best Day Spa + Med Spa in Austin of 2025 by the prestigious Evergreen Awards. This accolade highlights their exceptional contributions to the wellness and aesthetics industry, particularly their blend of clinical precision and personalized care. Known for offering a standout menu of evidence-based aesthetic and wellness services, the spa's commitment to the natural, sustainable approach to beauty is reflected in their award. Banyan & Bamboo's regenerative aesthetics, including neuromodulators, dermal fillers, biostimulants, and cutting-edge injectable wellness therapies, consistently deliver natural results, backed by advanced AI-powered skin analysis for hyper-customized facial treatment plans. This focus on personalized, regenerative aesthetics, combined with their holistic approach, has fostered loyalty and built lasting relationships with clients. Owner and Founder Jennifer Rushing's leadership and the spa's deep connection with their clients have played a pivotal role in the studio's success, creating an environment where beauty meets wellness in a thoughtful, intentional way. About Banyan & Bamboo Day Spa | Med Spa Banyan & Bamboo is a boutique day spa and med spa in Austin, TX, specializing in regenerative aesthetics and clinical wellness treatments. The women-led studio offers AI-driven skin analysis, facial balancing, PRF therapies, injectable wellness services, and customized treatment blueprints. Built on the belief that science and soul should coexist, the spa delivers natural-looking results that last - inside and out. Media Contact: Name: Jennifer Rushing Title: Owner & Founder Email: [email protected] Contact Info: Name: Jennifer Rushing Email: Send Email Organization: Banyan & Bamboo Website: Release ID: 89162872 Should any errors, concerns, or inconsistencies arise from the content provided in this press release that require attention or if a press release needs to be taken down, we kindly request that you immediately contact us at [email protected] (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our efficient team will be at your disposal for timely assistance within 8 hours – taking necessary measures to rectify identified issues or providing guidance on the removal process. We prioritize delivering accurate and reliable information.
